Asta Medica, Aktiengesellschaft

Encrypta Gmbh

Viatris Gmbh & Co Kg

Klaus Wessel

Heinz Ulrich

Harald Borbe

Helmut Hettche

Lester Packer

Hans Bisswanger

Amira Klip

J&uuml;rgen Engel

Michael Lobisch

Carl-Heinrich Weischer

Robert Hermann

Claudia Wicke

Mechthild Auge

Jean Schoenen

Manfred Peukert

The present invention relates to solid compositions comprising a substance which improves nitric oxide (NO) availability, re. an NO donor or a precursor of the biosynthesis of nitric oxide or an direct or indirect NO agonist, with arginine being a preferred compound, in combination with a dithiolane, with &#x3b1;-lipoic acid as a preferred compound, and its use for improvement of sexual function. The compositions according to the invention comprise the NO donor or its precursor in excess, based on the molar amount of the constituents. The compositions are also suited for the improvement of sexual function. In particular the present invention relates to the use of a dithiolane in combination with a NO donor or a precursor thereof for the preparation of a medication for treatment of sexual dysfunction.

Compositions comprising an NO donor and a dithiolane and their use for improvement of sexual function

The present invention relates to the use of R(+)-alpha-lipoic acid ((R)-5-(1,2-dithiolan-3-yl)valeric acid) and/or of a physiologically acceptable derivative of this compound for cryptogenic neuropathy.

Use of R(+)-alpha-lipoic acid for cryptogenic neuropathy

Racemic &agr;-lipoic acid or its enantiomers or pharmaceutically acceptable salts, esters or amides thereof can be administrated parenterally at a rate of 50 to 600 mg of active compound, based on racemic &agr;-lipoic acid, per minute.

Facilitated administration of &agr;-lipoic acid or derivatives thereof

Use of R-(&plus;)-&agr;-lipoic acid, R-(&minus;)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

The invention relates to the use of racemic &agr;-lipoic acid or its enantiomers or pharmaceutically acceptable salts, amides, esters or thioesters thereof, in reduced or oxidized form, as active ingredient in the prevention or the acute or chronic treatment of migraine.

Treatment of migraine by administration of &agr;-lipoic acid or derivatives thereof

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance. These drugs mentioned can also be used advantageously in combination with other antidiabetic drugs, particularly with insulin, and/or other additives or stabilizers or adjuvants, such as vitamin E, vitamin C, NADH, NADPH and ubiquinone. The invention furthermore relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, as well as their salts, esters and amides for the preparation of drugs for the treatment of diseases with limited function of or a lowered content of the glucose transporters.

Use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid and

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance.

Use of R-(+)-.alpha.-lipoic acid, R-(-)dihydrolipoic acid and

A pharmaceutical composition containing alpha-lipoic acid, dihydrolipoic acid, metabolites of alpha-lipoic acid (inter alia bisnortetralipoic acid and tetranorlipoic acid), optical isomers R- and S- forms of alpha-lipoic acid in oxidized and reduced form together with a vitamin, especially vitamins A, B1, B2, B6, B12, C and E and their pharmaceutically acceptable salts. The compositions are useful for producing analgesic, anti-inflammatory, antidiabetic, cytoprotective, anti-ulcer, antinecrotic, neuroprotective, detoxifying, anti-ischemic, liver function regulating, anti-allergic, immune-stimulating and antioncogenic effects.

Growing community of inventors

Bad Vilbel, Germany

Klaus Wessel